Evercore ISI Group analyst Ross Muken has maintained an Outperform rating on Icon (NASDAQ: ICLR) while raising the price target to $180 from $150. The adjustment reflects an updated valuation outlook for the company.

Rating and Price Target Details

The revised price target of $180 represents an increase from the previous target of $150. The Outperform rating indicates that the analyst expects the stock to perform better than the broader market average.

The report does not specify the timeframe for achieving the new price target.

Icon reported financial results for the first quarter ended March 31, 2026, with revenue reaching $2,034.0 million, a 0.9% increase compared to the prior year period. The clinical research organization posted an adjusted EBITDA of $317.7 million, representing 15.6% of revenue, while GAAP net income stood at $104.8 million. The company maintained strong commercial momentum, evidenced by net business wins of $2,880 million and a net book-to-bill ratio of 1.42, which drove a 4.0% increase in closing backlog to $22.7 billion.

CEO Mr. Barry Balf attributed the performance to robust gross award activity and low cancellations, supported by partnerships added in the second half of 2025 and two new partnerships during the quarter. Despite the impact of business mix on financial performance, management expressed confidence in executing its strategic plan throughout 2026. Net debt was $2.6 billion as of March 31, 2026, with a net debt to adjusted EBITDA ratio of 1.8x.

First Quarter 2026 Financial Highlights

Operational Performance

Gross bookings for the quarter totaled $3,263 million with cancellations of $383 million, determined under a new policy effective October 1, 2025. Free cash flow was $136.2 million, driven by $167.0 million in cash generated from operating activities and $30.8 million in capital expenditure. The company made $7.4 million in Term Loan B payments during the quarter. Cash and cash equivalents increased to $765.2 million from $647.3 million at the end of December 31, 2025.

Icon reaffirmed its full-year 2026 financial guidance, expecting revenue in the range of $7,850 million to $8,150 million and adjusted diluted earnings per share between $10.00 and $11.00. The revenue outlook compares to an analyst estimate of $8.022 billion, while the EPS guidance compares to a $10.55 estimate. The guidance excludes items such as amortization, stock-based compensation, foreign currency gains and losses, restructuring, and transaction-related costs.